Xenomics to Present Unique DNA Medical Diagnostic Platform at Rodman & Renshaw Healthcare Conference in Monaco; CEO Dr. David Tomei to Discuss Research Data and Potential Product Applications of Non-Invasive Tr-DNA Medical Testing Technology.

NEW YORK -- Xenomics, Inc. (OTCBB:XNOM) (FWB:XE7), a developer of next-generation medical DNA technologies, has announced that Dr. L. David Tomei Ph.D., Xenomic's CEO and co-founder, will present an overview of the Company's breakthrough medical diagnostic technologies and innovative clinical programs at the upcoming the Rodman & Renshaw 3rd Annual Global Healthcare Conference, a leading annual biotechnology forum for global investors and financial professionals.

"We look forward to sharing our latest clinical data and commercialization initiatives with colleagues in the scientific community and investors interested in promising, emerging-growth biotechnology opportunities," said Dr. Tomei.

Xenomic's proprietary Transrenal-DNA (Tr-DNA) medical diagnostic testing technology utilizes urine samples, rather than invasive blood or other samples, and thus could foster fundamental improvements in safety, accuracy and functionality of diagnostic testing in the field of molecular diagnostics, currently a $1.5 billion segment of the healthcare industry.

The Company recently announced that its research scientists had successfully identified DNA sequences of the H. pylori bacteria in the urine of infected patients. "This demonstrates the applicability of our non-invasive DNA-based urine test with bacterial pathogens and infectious diseases," commented Dr. Tomei. H. pylori bacteria causes 80% to 90% of duodenal and gastric ulcers. Many more individuals in the world's population are infected, but have no symptoms and are at increased risk for gastric cancer, mucosal-associated-lymphoid-type (MALT) lymphoma and other conditions.

The Rodman & Renshaw Healthcare Conference, to be attended by investors, venture capitalists, company executives, scientists and others, is scheduled for May 15-16 at the Le Meridien Beach Plaza Hotel, in Monte Carlo, Monaco.

Xenomics intends to use its Tr-DNA platform to develop and commercialize a new generation of completely safe and non-invasive medical testing DNA for the detection and/or monitoring of infectious diseases, including AIDS and tuberculosis, and for prenatal genetic testing, including gender determination, Down syndrome and other genetic disorders.

"Xenomics' proprietary technology platform has consistently demonstrated the potential to detect highly specific genetic markers from anything within the body possessing genetic information that is foreign. We're greatly encouraged that this medical testing platform could have a major transformative impact on the enormous diagnostic healthcare marketplace," said Dr. Tomei.

The 3rd Annual Rodman & Renshaw Healthcare Conference will also include presentations by an estimated 150 additional emerging-growth companies. For more information about the Rodman & Renshaw Healthcare Conference in Monaco, please visit http://www.rodmanandrenshaw.com.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company's prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/xenomics. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form SB-2 as filed with the Securities and Exchange Commission on March 15, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.